Clinical Trial

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-01-21; most recent amendment 2026-07-06.
Trial Details
NCT Number NCT07359859
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Incyte Corporation
Conditions Hematologic Malignancies
Enrollment 40 participants
Start Date 2026-01-20
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-07